{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:16:16Z","timestamp":1791645376773,"version":"4.3.4"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,10]]},"DOI":"10.1016\/j.pain.2004.07.004","type":"journal-article","created":{"date-parts":[[2004,8,11]],"date-time":"2004-08-11T10:34:09Z","timestamp":1092220449000},"page":"286-296","source":"Crossref","is-referenced-by-count":53,"title":["Efficacy and safety of valdecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials"],"prefix":"10.1097","volume":"111","author":[{"given":"Jayne E.","family":"Edwards","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry J.","family":"McQuay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-10-20210126","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1093\/rheumatology\/41.9.1008","article-title":"Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxen.","volume":"41","author":"Bensen","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"R3-10-20210126","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","article-title":"Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.","volume":"343","author":"Vigor Study Group, Bombardier","year":"2000","journal-title":"N Engl J Med"},{"key":"R4-10-20210126","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1136\/bmj.310.6977.452","article-title":"The number needed to treat: a clinically useful measure of treatment effect.","volume":"310","author":"Cook","year":"1995","journal-title":"Br Med J"},{"key":"R5-10-20210126","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1185\/030079902125000345","article-title":"GP and patient perspectives on treatment with non-steroidal anti-inflammatory drugs for the pain in osteoarthritis.","volume":"18","author":"Crichton","year":"2002","journal-title":"Curr Med Res Opinion"},{"key":"R6-10-20210126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmj.325.7365.619","article-title":"Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials.","volume":"325","author":"Deeks","year":"2002","journal-title":"Br Med J"},{"key":"R7-10-20210126","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S0140-6736(99)03057-3","article-title":"The epidemiology of chronic pain in the community.","volume":"354","author":"Elliott","year":"1999","journal-title":"Lancet"},{"key":"R8-10-20210126","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/01.EDE.0000034633.74133.C3","article-title":"Nonsteroidal antiinflammatory drugs as a trigger of clinical heart failure.","volume":"14","author":"Garcia-Rodriguez","year":"2003","journal-title":"Epidemiology"},{"key":"R10-10-20210126","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0304-3959(99)00302-4","article-title":"An evaluation of homogeneity tests in meta-analyses in pain using simulations of individual patient data.","volume":"85","author":"Gavaghan","year":"2000","journal-title":"Pain"},{"key":"R11-10-20210126","first-page":"38","article-title":"Persistence with COX-2 inhibitors in managed care: an analysis of claims data.","volume":"16","author":"Harley","year":"2003","journal-title":"Managed Care Interface"},{"key":"R12-10-20210126","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/1529-0131(200002)43:2<370::AID-ANR17>3.0.CO;2-D","article-title":"Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis.","volume":"43","author":"Hawkey","year":"2000","journal-title":"Arthritis Rheum"},{"key":"R13-10-20210126","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1136\/gut.52.6.820","article-title":"Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study.","volume":"52","author":"Rofecoxib Rheumatoid Arthritis Endoscopy Study Group, Hawkey","year":"2003","journal-title":"Gut"},{"key":"R14-10-20210126","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1046\/j.1365-2125.1997.00631.x","article-title":"Consumption of non-steroidal anti-inflammatory drugs and the development of functional renal impairment in elderly subjects. Results of a case-control study.","volume":"44","author":"Henry","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"R15-10-20210126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"R16-10-20210126","first-page":"530","article-title":"Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis.","volume":"51","author":"Kivitz","year":"2002","journal-title":"J Fam Pract"},{"key":"R17-10-20210126","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0016-5085(03)00900-4","article-title":"Gastrointestinal health care resource utilization with chronic use of COX-2-specific inhibitors versus traditional NSAIDs.","volume":"125","author":"Laine","year":"2003","journal-title":"Gastroenterology"},{"key":"R18-10-20210126","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1053\/joca.2001.0510","article-title":"Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen.","volume":"10","author":"Makarowski","year":"2002","journal-title":"Osteoarthritis Cartilage"},{"key":"R19-10-20210126","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1136\/bmj.325.7365.624","article-title":"Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs.","volume":"325","author":"Mamdani","year":"2002","journal-title":"Br Med J"},{"key":"R20-10-20210126","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0140-6736(99)04149-5","article-title":"Improving the quality of reports of meta-analyses of randomised controlled: the QUOROM statement.","volume":"354","author":"Moher","year":"1999","journal-title":"Lancet"},{"key":"R22-10-20210126","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3111\/199902045055","article-title":"Cost of NSAID adverse effects to the UK National Health Service.","volume":"2","author":"Moore","year":"1999","journal-title":"J Med Econ"},{"key":"R21-10-20210126","first-page":"6","article-title":"Sildenafil (Viagra) for male erectile dysfunction: a meta-analysis of clinical trial reports.","volume":"2","author":"Moore","year":"2002","journal-title":"BioMed Central Urol"},{"key":"R24-10-20210126","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1001\/archinte.160.6.777","article-title":"Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem.","volume":"160","author":"Page","year":"2000","journal-title":"Arch Intern Med"},{"key":"R25-10-20210126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/rheumatology\/keg359","article-title":"Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial.","volume":"42","author":"Pavelka","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"R26-10-20210126","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1097\/00042737-200210000-00011","article-title":"Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis.","volume":"14","author":"Sikes","year":"2002","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R27-10-20210126","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","article-title":"Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the class study: a randomized controlled trial. Celecoxib long-term arthritis safety study.","volume":"284","author":"Silverstein","year":"2000","journal-title":"J Am Med Assoc"},{"key":"R28-10-20210126","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0304-3959(00)00234-7","article-title":"Teasing apart quality and validity in systematic reviews: an example from acupuncture trials in chronic neck and back pain.","volume":"86","author":"Smith","year":"2000","journal-title":"Pain"},{"key":"R29-10-20210126","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0895-4356(00)00242-0","article-title":"Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature.","volume":"53","author":"Sterne","year":"2000","journal-title":"J Clin Epidemiol"},{"key":"R30-10-20210126","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0895-4356(99)00204-8","article-title":"Misleading funnel plot for detection of bias in meta-analysis.","volume":"53","author":"Tang","year":"2000","journal-title":"J Clin Epidemiol"},{"key":"R31-10-20210126","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0304-3959(99)00267-5","article-title":"Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use.","volume":"85","author":"Tramer","year":"2000","journal-title":"Pain"}],"container-title":["Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00006396-200410000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:25:21Z","timestamp":1785785121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006396-200410000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004]]}},"URL":"https:\/\/doi.org\/10.1016\/j.pain.2004.07.004","relation":{},"ISSN":["0304-3959"],"issn-type":[{"value":"0304-3959","type":"print"}],"subject":[],"published":{"date-parts":[[2004,10]]}}}